scholarly article | Q13442814 |
P50 | author | Maria C Carrillo | Q51070685 |
Ricardo S Osorio | Q57001600 | ||
Steven E. Arnold | Q64157128 | ||
Zahinoor Ismail | Q87798445 | ||
Constantine G. Lyketsos | Q91213781 | ||
David S. Miller | Q118299151 | ||
Sonia Ancoli-Israel | Q37322997 | ||
Clive Ballard | Q40279915 | ||
Krista L Lanctôt | Q42725631 | ||
Jiska Cohen-Mansfield | Q44627653 | ||
P2093 | author name string | Andrew Satlin | |
Lisa J Bain | |||
Paul B Rosenberg | |||
David Steffens | |||
Joan Amatniek | |||
James A Hendrix | |||
Brendon Boot | |||
Pierre Tariot | |||
Erik Musiek | |||
Heidi Jurgens | |||
P2860 | cites work | Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease | Q48599203 |
Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study | Q48669455 | ||
Family, Alzheimer's disease and negative symptoms | Q48684723 | ||
Apathy and depression in mild Alzheimer's disease: a cross-sectional study using diagnostic criteria | Q48690050 | ||
Neuropathologic and neurochemical correlates of psychosis in primary dementia | Q48717187 | ||
Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat. | Q48738385 | ||
Reliability and validity of the apathy evaluation scale | Q48866734 | ||
Substantia nigra tangles are related to gait impairment in older persons | Q50279058 | ||
CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial. | Q50606263 | ||
The incremental direct costs associated with behavioral symptoms in AD. | Q50711680 | ||
The measurement of psychosis in dementia: a comparison of assessment tools. | Q51749556 | ||
Psychotic symptoms in dementia and the rate of cognitive decline. | Q52041977 | ||
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. | Q52056472 | ||
Associations of psychotic symptoms in dementia sufferers. | Q53213623 | ||
Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. | Q53216036 | ||
The stress and psychological morbidity of the Alzheimer patient caregiver. | Q53230330 | ||
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. | Q53274559 | ||
Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. | Q53338995 | ||
Assessment of Agitation in Older Adults | Q60298805 | ||
Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and H | Q61902867 | ||
Major and minor depression in Alzheimer's disease: prevalence and impact | Q74108883 | ||
The epidemiology of psychosis in dementia | Q78792553 | ||
Pharmacotherapies for sleep disturbances in Alzheimer's disease | Q24197895 | ||
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle | Q24644961 | ||
The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders | Q26823480 | ||
Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? | Q26827219 | ||
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future | Q26864905 | ||
Assessment and management of behavioral and psychological symptoms of dementia | Q28088782 | ||
Sleep drives metabolite clearance from the adult brain | Q29620065 | ||
Decoupling of the brain's default mode network during deep sleep | Q30484161 | ||
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials | Q33153605 | ||
Measurement of inappropriate behavior associated with dementia. | Q33646486 | ||
Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis | Q33668661 | ||
Sertraline for the treatment of depression in Alzheimer disease | Q33741090 | ||
Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study | Q33753288 | ||
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial | Q33863623 | ||
Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease | Q34090664 | ||
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study | Q34100750 | ||
Neuroimaging of delusions in Alzheimer's disease. | Q34306435 | ||
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial | Q34370011 | ||
Regional cerebral blood flow changes as a function of delta and spindle activity during slow wave sleep in humans. | Q34427637 | ||
Research Domain Criteria: toward future psychiatric nosologies | Q34476922 | ||
Amnestic mild cognitive impairment and incident dementia and Alzheimer's disease in geriatric depression | Q34490382 | ||
The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis | Q34500657 | ||
Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease | Q34708307 | ||
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition | Q34992886 | ||
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study | Q35004787 | ||
The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline | Q35015551 | ||
"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis | Q35106233 | ||
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial | Q35109857 | ||
The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach | Q35111772 | ||
Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trial | Q35171044 | ||
Early neurone loss in Alzheimer's disease: cortical or subcortical? | Q35176873 | ||
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. | Q35218921 | ||
Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study | Q35240761 | ||
Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study | Q35561413 | ||
Sleep-disordered breathing advances cognitive decline in the elderly | Q35611633 | ||
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women | Q35630404 | ||
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. | Q35630897 | ||
Neuropsychiatric symptoms in Alzheimer's disease | Q35823575 | ||
The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. | Q35858684 | ||
Magnitude and causes of bias among family caregivers rating Alzheimer disease patients | Q35899036 | ||
Citalopram for agitation in Alzheimer's disease: design and methods | Q35905635 | ||
The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment | Q36149767 | ||
The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. | Q36191996 | ||
Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment | Q36385255 | ||
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women | Q36694340 | ||
Sleep quality and preclinical Alzheimer disease | Q36913338 | ||
Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study | Q36978103 | ||
Predictors of progression to severe Alzheimer's disease in an incidence sample | Q37218809 | ||
β-amyloid dynamics in human plasma | Q37254727 | ||
Modulation of the brain's functional network architecture in the transition from wake to sleep | Q37263065 | ||
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. | Q37383982 | ||
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid | Q37432083 | ||
Continuous positive airway pressure deepens sleep in patients with Alzheimer's disease and obstructive sleep apnea | Q37439204 | ||
Late-life depression, mild cognitive impairment, and dementia: possible continuum? | Q37682019 | ||
Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy | Q37788481 | ||
Neurobiology of delusions in Alzheimer's disease. | Q37853072 | ||
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial | Q37901878 | ||
Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes | Q38053311 | ||
Efficacy of nonpharmacologic interventions for agitation in advanced dementia: a randomized, placebo-controlled trial | Q38462691 | ||
Rethinking Psychosis in Dementia: An Analysis of Antecedents and Explanations | Q38806621 | ||
Monoaminergic neuropathology in Alzheimer's disease | Q38809649 | ||
Apathy associated with neurocognitive disorders: Recent progress and future directions. | Q38846813 | ||
AVP-786 for the treatment of agitation in dementia of the Alzheimer's type | Q39034436 | ||
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. | Q40502916 | ||
Quality of life in dementia patients in long-term care | Q40777926 | ||
Dementia in institutionalized elderly: relation to sleep apnea | Q41180232 | ||
Grey matter atrophy in mild cognitive impairment / early Alzheimer disease associated with delusions: a voxel-based morphometry study | Q41475094 | ||
Pathological alterations in the amygdala in Alzheimer's disease | Q41767135 | ||
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations | Q42381174 | ||
The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease | Q42470207 | ||
Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease | Q42492635 | ||
Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. | Q42492680 | ||
Depression in Alzheimer's disease: the effect of serotonin receptor gene variation | Q44411869 | ||
Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis | Q44450158 | ||
Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. | Q44513123 | ||
Behavioral symptoms in mild cognitive impairment | Q44840318 | ||
Poor sleep quality impairs cognitive performance in older adults | Q45767463 | ||
Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients | Q46040803 | ||
Nonpharmacologic treatment of behavioral disorders in dementia | Q46240025 | ||
Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia | Q46304586 | ||
Sleep-disordered breathing and cognition in older women | Q46447954 | ||
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. | Q47272225 | ||
The meanings of delusions in dementia: a preliminary study | Q47584510 | ||
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial | Q47641602 | ||
Self-reported sleep disturbance is associated with Alzheimer's disease risk in men. | Q48013471 | ||
Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. | Q48022782 | ||
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease | Q48150612 | ||
Sleep disturbance is associated with incident dementia and mortality | Q48162950 | ||
Variations in connectivity in the sensorimotor and default-mode networks during the first nocturnal sleep cycle. | Q48232326 | ||
Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders | Q48298818 | ||
Development of the brain's default mode network from wakefulness to slow wave sleep | Q48316407 | ||
Development of a large-scale functional brain network during human non-rapid eye movement sleep | Q48343413 | ||
Differences in brain metabolism associated with agitation and depression in Alzheimer's disease | Q48419321 | ||
P433 | issue | 3 | |
P921 | main subject | Alzheimer's disease | Q11081 |
P304 | page(s) | 440-449 | |
P577 | publication date | 2017-08-05 | |
P1433 | published in | Alzheimer's & dementia (New York, N. Y.) | Q27726239 |
P1476 | title | Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms | |
P478 | volume | 3 |
Q92377056 | A human memory circuit derived from brain lesions causing amnesia |
Q90248276 | A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia |
Q92210508 | Behavioral Disturbances in Dementia and Beyond: Time for a New Conceptual Frame? |
Q50199042 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects |
Q92128709 | Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice |
Q99592757 | Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition |
Q91410950 | Dementia in Down syndrome: unique insights for Alzheimer disease research |
Q90124631 | Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults |
Q64282137 | Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study |
Q58077250 | Extracellular Vesicles in Psychiatry Research in the Context of RDoC Criteria |
Q91781569 | Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1 |
Q52608019 | Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. |
Q92051615 | Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases |
Q93016317 | Multilevel Impacts of Iron in the Brain: The Cross Talk between Neurophysiological Mechanisms, Cognition, and Social Behavior |
Q64868646 | Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease |
Q64910410 | Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. |
Q91715548 | Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach |
Q92101808 | Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA |
Q58124331 | New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis |
Q99544929 | Remodeling of projections from ventral hippocampus to prefrontal cortex in Alzheimer's mice |
Q93391029 | Reproducibility of brain MRS in older healthy adults at 7T |
Q49962834 | Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia |
Q90638313 | Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions |
Q64252307 | The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature |
Q90704728 | The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions |
Q92535704 | The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease |
Q57495494 | The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease |
Q88931208 | The influence of the individual neuropsychiatric symptoms of people with Alzheimer disease on family caregiver distress-A longitudinal ALSOVA study |
Q91620137 | The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents |
Q64101560 | Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers |
Q102209096 | Trajectories and risk factors of dementia progression: a memory clinic cohort followed up to 3 years from diagnosis |
Q91326936 | Unmet needs in community-living persons with dementia are common, often non-medical and related to patient and caregiver characteristics |
Search more.